Using angiogenic factors and their soluble receptors to predict organ dysfunction in patients with disseminated intravascular coagulation associated with severe trauma

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Wada, Takeshi ^a   Jesmin, Subrina ^a,b,c   Gando, Satoshi ^a   Sultana, Sayeeda N ^b,c   Zaedi, Sohel ^b,c   Yokota, Hiroyuki ^d  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c Probal Housing Ltd   (Bangladesh)

^d NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; LACTIC ACID; VASCULOTROPIN RECEPTOR 1; ANGIOGENIC PROTEIN; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HUMAN; INJURY; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PREDICTIVE VALUE; PRIORITY JOURNAL; THROMBOCYTE COUNT; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPLICATION; INJURY SCALE; MIDDLE AGED; NONPARAMETRIC TEST; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; ANGIOGENIC PROTEINS; BIOMARKERS; CASE-CONTROL STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; REGRESSION ANALYSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TRAUMA SEVERITY INDICES;

EID: 84859898999     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11309     Document Type: Article

References (48)

1. Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg 2011, 254:10-19. 10.1097/SLA.0b013e31821221b1, 21368657.
2. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008, 65:748-754. 10.1097/TA.0b013e3181877a9c, 18849786.
3. Gando S. Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path. J Trauma 2009, 67:381-383. 10.1097/TA.0b013e3181a84f63, 19667894.
4. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami K. Disseminated intravascular coagulation with a fibrinolytic phenotype at an early phase of trauma predicts mortality. Thromb Res 2009, 124:608-613. 10.1016/j.thromres.2009.06.034, 19660788.
5. Gando S. Disseminated intravascular coagulation in trauma patients. Semin Thromb Hemost 2001, 27:585-592. 10.1055/s-2001-18864, 11740682.
6. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77:527-543. 10.1007/s001099900019, 10494799.
7. van Meurs M, Kumpers P, Ligtenberg JJ, Meertens JH, Molema G, Zijlstra JG. Bench-to-bedside review: Angiopoietin signalling in critical illness - a future target?. Crit Care 2009, 13:207. 10.1186/cc7153, 2689450, 19435476.
8. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 2006, 27:552-558. 10.1016/j.it.2006.10.004, 17045842.
9. Ricciuto DR, Dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, Lafferty EI, Cook DJ, Fox-Robichaud A, Kahnamoui K, Kain KC, Liaw PC, Liles WC. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011, 39:702-710. 10.1097/CCM.0b013e318206d285, 21242795.
10. Brindle NP, Saharinen P, Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 2006, 98:1014-1023. 10.1161/01.RES.0000218275.54089.12, 2270395, 16645151.
11. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277:55-60. 10.1126/science.277.5322.55, 9204896.
12. Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL, Rahn P, Christiaans SC, Bir ND, Pittet JF. Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?. Ann Surg 2008, 247:320-326. 10.1097/SLA.0b013e318162d616, 18216540.
13. Ong T, McClintock DE, Kallet RH, Ware LB, Matthay MA, Liu KD. Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients. Crit Care Med 2010, 38:1845-1851. 10.1097/CCM.0b013e3181eaa5bf, 20581666.
14. Grad S, Ertel W, Keel M, Infanger M, Vonderschmitt DJ, Maly FE. Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med 1998, 36:379-383.
15. Giamarellos-Bourboulis EJ, Kanellakopoulou K, Pelekanou A, Tsaganos T, Kotzampassi K. Kinetics of angiopoietin-2 in serum of multi-trauma patients: correlation with patient severity. Cytokine 2008, 44:310-313. 10.1016/j.cyto.2008.09.003, 18952457.
16. Civil ID, Schwab CW. The Abbreviated Injury Scale, 1985 revision: a condensed chart for clinical use. J Trauma 1988, 28:87-90. 10.1097/00005373-198801000-00012, 3339667.
17. Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011, 377:1096-1101. 1101 e1091-1092.
18. Hayakawa M, Sawamura A, Gando S, Kubota N, Uegaki S, Shimojima H, Sugano M, Ieko M. Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase. Surgery 2011, 149:221-230. 10.1016/j.surg.2010.06.010, 20655560.
19. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008, 36:145-150. 10.1097/01.CCM.0000295317.97245.2D, 18090367.
20. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
21. Sawamura A, Hayakawa M, Gando S, Kubota N, Sugano M, Wada T, Katabami K. Application of the Japanese Association for Acute Medicine disseminated intravascular coagulation diagnostic criteria for patients at an early phase of trauma. Thromb Res 2009, 124:706-710. 10.1016/j.thromres.2009.06.036, 19651430.
22. Murakami H, Gando S, Hayakawa M, Sawamura A, Sugano M, Kubota N, Uegaki S, Jesmin S. Disseminated Intravascular Coagulation (DIC) at an early phase of trauma continuously proceeds to DIC at a late phase of trauma. Clin Appl Thromb Hemost 2012,
23. Ikegami K, Suzuki Y, Yukioka T, Matsuda H, Shimazaki S. Endothelial cell injury, as quantified by the soluble thrombomodulin level, predicts sepsis/multiple organ dysfunction syndrome after blunt trauma. J Trauma 1998, 44:789-794. discussion 794-785, 10.1097/00005373-199805000-00008, 9603079.
24. Mankhambo LA, Banda DL, Jeffers G, White SA, Balmer P, Nkhoma S, Phiri H, Molyneux EM, Hart CA, Molyneux ME, Heyderman RS, Carrol ED. The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Crit Care 2010, 14:R91. 10.1186/cc9025, 2911728, 20492647.
25. Karlsson S, Pettila V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E. Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 2008, 106:1820-1826. 10.1213/ane.0b013e31816a643f, 18499616.
26. Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005, 24:508-512. 10.1097/01.shk.0000190827.36406.6e, 16317379.
27. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC, Ngo L, Angus DC, Aird WC. A prospective, observational study of soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock 2008, 29:452-457. 10.1097/SHK.0b013e31815072c1, 18598002.
28. Yang KY, Liu KT, Chen YC, Chen CS, Lee YC, Perng RP, Feng JY. Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Crit Care 2011, 15:R11. 10.1186/cc9412, 3222041, 21219633.
29. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 1998, 94:395-404.
30. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997, 3:2187-2190.
31. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997, 94:663-668. 10.1073/pnas.94.2.663, 19570, 9012841.
32. Vidal F, Aragones J, Alfranca A, de Landazuri MO. Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood 2000, 95:3387-3395.
33. Alves BE, Montalvao SA, Aranha FJ, Lorand-Metze I, De Souza CA, Annichino-Bizzacchi JM, De Paula EV. Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. J Transl Med 2011, 9:23. 10.1186/1479-5876-9-23, 3058017, 21371321.
34. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 2001, 33:409-420. 10.1016/S1357-2725(01)00026-7, 11312109.
35. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006, 203:1447-1458. 10.1084/jem.20060375, 2118329, 16702604.
36. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005, 109:227-241.
37. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I, Sotiropoulou C, Zakynthinos S, Armaganidis A, Papapetropoulos A, Roussos C. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 2007, 35:199-206. 10.1097/01.CCM.0000251640.77679.D7, 17110873.
38. Giuliano JS, Lahni PM, Harmon K, Wong HR, Doughty LA, Carcillo JA, Zingarelli B, Sukhatme VP, Parikh SM, Wheeler DS. Admission angiopoietin levels in children with septic shock. Shock 2007, 28:650-654. 2754128, 18092380.
39. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008, 63:903-909. 10.1136/thx.2007.087387, 18559364.
40. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, Sukhatme VP. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006, 3:e46. 10.1371/journal.pmed.0030046, 1334221, 16417407.
41. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000, 6:460-463. 10.1038/74725, 10742156.
42. Reusch P, Barleon B, Weindel K, Martiny-Baron G, Godde A, Siemeister G, Marme D. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 2001, 4:123-131. 10.1023/A:1012226627813, 11806244.
43. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007, 27:2619-2626. 10.1161/ATVBAHA.107.150482, 17901375.
44. van der Heijden M, van Nieuw Amerongen GP, van Hinsbergh VW, Groeneveld AB. The interaction of soluble Tie2 with angiopoietins and pulmonary vascular permeability in septic and nonseptic critically ill patients. Shock 2010, 33:263-268. 10.1097/SHK.0b013e3181b2f978, 19543148.
45. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009, 29:2011-2022. 10.1128/MCB.01472-08, 2663314, 19223473.
46. Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010, 38:S35-42.
47. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684. 10.1038/nm0603-677, 12778166.
48. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999, 274:15732-15739. 10.1074/jbc.274.22.15732, 10336473.